ment procedures for isolating the peptides from plasma, using an adsorption column (e.g., Sep-Pak C18). The pretreatment might selectively separate the ET-rich fraction, free from huge amounts of plasma proteins, thereby enhancing specificity and sensitivity, but the yield in the step determines the assay precision. The contribution of a precursor of ET-1, big ET-1, or proendothelin-1, that is identified in plasma two times more than ET-15 and easily makes a cross reaction with genuine ET-1, should be considered.
There might be a well-organized system to regulate vascular tonus and/or mitogenesis of vascular smooth muscle cells with several autacoids in the media of the vessel wall in physiological states and the subendothelial space in atherosclerotic lesions. No systematic scheme has been presented to govern the stimulation or inhibition of the synthesis, secretion, or inactivation of these substances, although some functional interaction between ET-1 and endothelium-derived relaxing factor (EDRF) has been suggested. 6 The local concentration of the ET family is obviously more significant than the systemic concentration, but no strategy is available now for assay of the local level. Furthermore, we have no convincing data on the directional secretion or partition of these substances between the luminal bloodstream and abluminal uptake to underlying smooth muscle cells. In addition to endothelial cells, several tissues, including vascular smooth muscle cells themselves after stimulation by angiotensin II or polymorphonuclear leukocytes, synthesize or metabolize big ET-1 and ET-1 by an autocrine or paracrine mechanism.7 It should also be mentioned that vascular smooth muscle cells do not homogeneously respond to these vasoactive stimuli both in vitro and in vivo28 but are influenced by the development stage, cell-cycle, or cytodifferentiation.9 It is fascinating to recognize the interactions of these endothelium-derived vasoactive substances not only in cell biology but also in clinical science,10 which leaves so many problems to be resolved in vascular medicine.
Teruhiko Toyo-oka, MD Tsuneaki Sugimoto, MD The usefulness of left ventricular ejection fraction as an end point of thrombolytic trials was discussed in a recent article. 1 We disagree with a number of the statements made. First, left ventricular function remains a very important prognostic factor after myocardial infarction in the thrombolytic era. [2] [3] [4] [5] In the Interuniversity study,2 which has reported 5-year follow-up after thrombolytic therapy, left ventricular function was the most important prognostic factor, whereas patency of the infarct-related artery was not predictive. The TAMI trials also showed that ejection fraction was the most powerful prognostic factor.3 The Western Washington intracoronary trial was quoted as showing that patency of the infarct-related artery, and not left ventricular function, related to 12-month survival. In fact, in this trial, when left ventricular function was assessed on day 3 (rather than acutely, when there is severe myocardial stunning and hyperkinesis of noninfarct zones), ejection fraction was the most important prognostic factor.4 Also, in the Western Washington intravenous rt-PA trial, left ventricular function was the most important prognostic factor. 5 Second, we think imputation is inappropriate and fallacious. However, in our study of rt-PA versus streptokinase,6 imputation of ejection fraction of 0% to patients dying before left ventricular function could be measured did not change the conclusion of the study that these agents produce similar preservation of ejection fraction. Regional wall motion corrected for the area of myocardium at risk was also identical in the two groups.7
Third, the fact that despite the performance of large trials and the expenditure of a great deal of effort, no difference has been established as yet between the major thrombolytic regimens with regard to mortality,8 and left ventricular function6,9 should not be taken to mean that methods for assessment of efficacy have been faulty; rather it means that on present evidence no difference in efficacy exists. In our laboratory, the normal ejection fraction is 71+7% and after a first infarction 53-+-13%.10 Thrombolysis with presently available drugs improves the ejection fraction to 59+10%, thus achieving only about one third of the potential preservation.11 Therefore, considerable potential for improvement exists in our therapies.
Fourth, there are limitations to the end points suggested. We believe that the important factors are: 1) whether patients die; 2) whether they have a major effect such as a stroke, the degree of residual disability being more important than etiology; and 3) whether the patient is left with factors that adversely affect subsequent survival.
Left ventricular function is clearly the most important factor predicting long-term outcome,2-5 although other factors such as patency of the infarct-related artery and inducible arrhythmias at electrophysiologic study could also be considered. 12 Finally, the "consumer's report approach," although superficially attractive, has serious limitations. There are major conceptual issues with respect to combining end points such as death, where trials of over 20,000 patients may be required, with more frequent and less meaningful end points, such as recurrent ischemia, for which 200 patients may suffice.
As we have previously stated,'0 small trials measuring meaningful end points such as ejection fraction or end-systolic volume'3 are required to fine-tune therapy, and large trials are required as well to assess mortality. This is particularly important with thrombolytic therapy, where the treatment can benefit patients by improving left ventricular function, but can also cause harm. Harvey 
Reply
We appreciate the interest that Dr. White and his colleagues have taken in our discussion of end points of trials of thrombolytic therapy. We would like to comment on each of their assertions.
Dr. White states that left ventricular function is important for prognosis. We have never said otherwise. Our own manuscripts have documented the substantial relation between left ventricular function and subsequent death. We merely stated that it is not the only important factor and that it is usually not measured in every patient.
The next statement is that imputation is "inappropriate and fallacious." This is a broad and sweeping statement, and they offer no evidence in its support other than the results of one of their own trials. Important issues such as the need for imputation, which have been the subject of much discussion and debate and other disciplines besides cardiology, need more scholarly debate and consideration. We have not advocated imputation of data, but rather we are raising the issue as a prototypical deficiency of the left ventricular function end point.
Dr. White and his colleagues seem to be emersed in the t-PA versus streptokinase debate rather than considering the relevance of our discussion to the multitude of ancillary and adjunctive therapies now becoming available. We certainly agree that when large trials can be done, differences in efficacy should be detectable without the need for sensitive composite end points. However, we simply cannot do a large trial to evaluate every permutation of acute MI care.
We mostly agree with the fourth point raised by Dr. White and colleagues (that mortality should remain the most important end point), but we hope they can realize that if mortality rates are equal between two therapies, nonfatal morbidity and cost differences can and should lead to valid measures of true differences between therapies. Most other fields of medicine have understood this point for many years. Since most patients do not die, the other end points are extremely important to patients who survive the acute event. Furthermore, are the authors arguing that acute ischemia and reocclusion are not associated with increased mortality and morbidity, or that patients with symptomatic heart failure are not at increased risk of death? Most cardiologists would accept these measures as indicators of high mortality, and in fact, all of our data and that of others indicate that these clinical factors add to measures of systolic left ventricular function in terms of prognostic stratification.
In their final argument, White and colleagues choose to dismiss the consumer reports approach as "superficially attractive" and then to close by stating that only two types of trials should be done, those assessing left ventricular function and those assessing mortality. We suggest that White and colleagues should consider other end points with a less superficial argument than made in their letter. What are the conceptual issues, and how would they deal with missing end points?
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